Back to Crizotinib

Crizotinib

Showing 3 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	6	62	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	Multi-target TKI	Crizotinib	—	Missing	intra-cranial	brain	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	1	62	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	Multi-target TKI	Crizotinib	—	Missing	extra-cranial	lung	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Keane et al.	2025	Prospective	Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.	10.1016/j.ijrobp.2024.10.022	NCT02314364	1	59	Lung cancer	metastatic	Multi-target TKI	Crizotinib	—	1	extra-cranial	spine, lung	—	44.0	35.0	50.0	5	4	6	Missing	Missing	Missing	RT-related	—	—	0	—	—	—	—